Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Schizophr Res. 2018 Apr 5;199:285–291. doi: 10.1016/j.schres.2018.03.037

Figure 3.

Figure 3

Distribution of mean values of memantine sensitivity (response after memantine minus response after placebo) for SZ subjects in the measures shown in Figure 2: MMN and ASSR (Gamma Band Power and Coherence) and PPI (Swerdlow et al. 2016; Light et al. 2017). Units are shown below each distribution. As a group, patients exhibited a significant increase in each EAIP measure after memantine, there was clear response heterogeneity. We propose to use this hetereogeneous EAIP response to acute drug challenge as evidence for available neuroplasticity within neurocognition-relevant brain mechanisms (EAIP), and hence as a biomarker to predict therapeutic sensitivity (example shown for PPI, based on a median split of MEM sensitivity).